CeriBell’s (NASDAQ:CBLL) Lock-Up Period Will End on April 9th

CeriBell’s (NASDAQ:CBLL) lock-up period is set to end on Wednesday, April 9th. CeriBell had issued 10,606,060 shares in its public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. After the end of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CBLL shares. TD Cowen boosted their price objective on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research note on Friday. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $32.50.

CeriBell Stock Down 1.5 %

NASDAQ:CBLL opened at $18.44 on Friday. The stock’s 50-day simple moving average is $21.95. CeriBell has a one year low of $17.67 and a one year high of $32.75.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. On average, equities analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC bought a new stake in shares of CeriBell during the 4th quarter valued at about $128,120,000. TPG GP A LLC purchased a new stake in CeriBell in the fourth quarter valued at approximately $102,677,000. Red Tree Management LLC bought a new stake in CeriBell during the fourth quarter valued at approximately $57,083,000. Yu Fan purchased a new position in CeriBell in the 4th quarter worth approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in shares of CeriBell in the 4th quarter worth $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.